{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:48:17Z","timestamp":1789678097383,"version":"4.0.1"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","sleep-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Sleep Medicine"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.sleep.2017.03.012","type":"journal-article","created":{"date-parts":[[2017,3,30]],"date-time":"2017-03-30T16:38:53Z","timestamp":1490891933000},"page":"105-108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"C","title":["Treatment of restless legs syndrome with the selective AMPA receptor antagonist perampanel"],"prefix":"10.1016","volume":"34","author":[{"given":"Diego","family":"Garcia-Borreguero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1543-7187","authenticated-orcid":false,"given":"Irene","family":"Cano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jose","family":"Granizo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.sleep.2017.03.012_bib1","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.sleep.2013.05.016","article-title":"The long-term treatment of restless legs syndrome\/Willis\u2013Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group","volume":"14","author":"Garcia-Borreguero","year":"2013","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2017.03.012_bib2","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.sleep.2012.08.004","article-title":"Long-term use of pramipexole in the management of restless legs syndrome","volume":"13","author":"Lipford","year":"2012","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2017.03.012_bib3","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.sleep.2010.11.002","article-title":"A\u00a010-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome","volume":"12","author":"Silver","year":"2011","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2017.03.012_bib4","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.sleep.2015.05.028","article-title":"Natural course of restless legs syndrome\/Willis\u2013Ekbom disease: long-term observation of a large clinical cohort","volume":"16","author":"Mitterling","year":"2015","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2017.03.012_bib5","doi-asserted-by":"crossref","first-page":"e108021","DOI":"10.1371\/journal.pone.0108021","article-title":"Perampanel inhibition of AMPA receptor currents in cultured hippocampal neurons","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.sleep.2017.03.012_bib6","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.sleep.2014.03.025","article-title":"Restless legs syndrome\/Willis\u2013Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria\u2013history, rationale, description, and significance","volume":"15","author":"Allen","year":"2014","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2017.03.012_bib7","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.5665\/sleep.2820","article-title":"Validation of the multiple suggested immobilization test: a test for the assessment of severity of restless legs syndrome (Willis\u2013Ekbom disease)","volume":"36","author":"Garcia-Borreguero","year":"2013","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2017.03.012_bib8","series-title":"The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications","author":"Iber","year":"2007"},{"key":"10.1016\/j.sleep.2017.03.012_bib9","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/brain\/awm244","article-title":"Where dopamine meets opioids: a meta-analysis of the placebo effect in restless legs syndrome treatment studies","volume":"131","author":"Fulda","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.sleep.2017.03.012_bib10","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1212\/WNL.0b013e318294b3f6","article-title":"Thalamic glutamate\/glutamine in restless legs syndrome: increased and related to disturbed sleep","volume":"80","author":"Allen","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.sleep.2017.03.012_bib11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.tins.2007.03.008","article-title":"D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons","volume":"30","author":"Surmeier","year":"2007","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.sleep.2017.03.012_bib12","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/mds.21533","article-title":"Pathophysiological concepts of restless legs syndrome","volume":"22","author":"Paulus","year":"2007","journal-title":"Mov Disord"}],"container-title":["Sleep Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S138994571730148X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S138994571730148X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T00:00:30Z","timestamp":1535932830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S138994571730148X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":12,"alternative-id":["S138994571730148X"],"URL":"https:\/\/doi.org\/10.1016\/j.sleep.2017.03.012","relation":{},"ISSN":["1389-9457"],"issn-type":[{"value":"1389-9457","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of restless legs syndrome with the selective AMPA receptor antagonist perampanel","name":"articletitle","label":"Article Title"},{"value":"Sleep Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sleep.2017.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}